On August 13, Liquidia Technologies Inc declined 5.06% in regular trading, trading at $74.885/share with turnover of $148 million, as investors continued to digest the company's second-quarter earnings report.

On the news front, the company reported Q2 earnings of $0.74 per diluted share, missing the FactSet consensus estimate of $0.76 and the LSEG estimate of $0.7722. Revenue surged approximately 18.5x year-over-year to $171.7 million, with core product YUTREPIA net sales reaching approximately $170.4 million, up 31% sequentially, and unique patient prescriptions reaching approximately 5,900. While revenue exceeded the consensus expectation of $168.5 million, the EPS shortfall prompted profit-taking given the stock had more than doubled year-to-date. Additionally, BofA Securities had previously downgraded the stock to Neutral from Buy with a $79 price target, adding further pressure to sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)